Small Cell Lung Cancer ( SCLC ) Clinical Trials

24 recruitingLast updated: June 17, 2026

There are 24 actively recruiting small cell lung cancer ( sclc ) clinical trials across 45 countries. Studies span Phase 2, Phase 1, Early Phase 1, Phase 3. Top locations include Omaha, Nebraska, United States, San Antonio, Texas, United States, Barcelona, Spain. Updated daily from ClinicalTrials.gov.


Small Cell Lung Cancer ( SCLC ) Trials at a Glance

24 actively recruiting trials for small cell lung cancer ( sclc ) are listed on ClinicalTrialsFinder across 6 cities in 45 countries. The largest study group is Phase 2 with 14 trials, with the heaviest enrollment activity in Omaha, San Antonio, and Barcelona. Lead sponsors running small cell lung cancer ( sclc ) studies include Pfizer, Radiopharm Theranostics, Ltd, and Bindu R Potugari.

Browse small cell lung cancer ( sclc ) trials by phase

Treatments under study

About Small Cell Lung Cancer ( SCLC ) Clinical Trials

Looking for clinical trials for Small Cell Lung Cancer ( SCLC )? There are currently 24 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Small Cell Lung Cancer ( SCLC ) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Small Cell Lung Cancer ( SCLC ) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 24 trials

Recruiting
Phase 1

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Metastatic Castration-resistant Prostate Cancer (mCRPC)Small Cell Lung Cancer ( SCLC )Follicular Lymphoma ( FL)
Pfizer453 enrolled83 locationsNCT03460977
Recruiting
Phase 1

THE-0504 in Patients With Solid Tumors

Triple-Negative Breast CancerGastric Cancer (GC)Small Cell Lung Cancer ( SCLC )+2 more
Thena Biotech S.r.l.30 enrolled1 locationNCT07646106
Recruiting
Phase 1

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

Gastric CancerHead and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)+9 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.40 enrolled3 locationsNCT07517198
Recruiting
Phase 3

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy

Extensive-stage Small Cell Lung Cancer (ES-SCLC)Small Cell Lung Cancer ( SCLC )
Boehringer Ingelheim670 enrolled236 locationsNCT07472517
Recruiting
Phase 2

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

Lung NeoplasmsSmall Cell Lung CancerSmall Cell Lung Cancer ( SCLC )+3 more
Pfizer40 enrolled12 locationsNCT07476287
Recruiting
Phase 2Phase 3

Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

Small Cell Lung Cancer ( SCLC )
Pfizer550 enrolled43 locationsNCT07226999
Recruiting
Phase 1

Safety and Preliminary Activity of BI115 in Advanced SCLC

Small Cell Lung Cancer ( SCLC )
Innovent Biologics (Suzhou) Co. Ltd.150 enrolled1 locationNCT07559019
Recruiting
Phase 1Phase 2

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

Small Cell Lung Cancer ( SCLC )Large Cell Neuroendocrine CarcinomaLarge Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)+4 more
Molecular Partners AG138 enrolled5 locationsNCT07278479
Recruiting

Establishment of a Prospective Clinical Cohort of Small Cell Lung Cancer Patients Receiving Radiotherapy-Involved Comprehensive Treatment

RadiotherapyImmunotherapySmall Cell Lung Cancer ( SCLC )+1 more
Shanghai Chest Hospital500 enrolled1 locationNCT07565532
Recruiting
Phase 2

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Extensive-stage Small Cell Lung Cancer (ES-SCLC)Small Cell Lung Cancer ( SCLC )
Bindu R Potugari35 enrolled1 locationNCT07339059
Recruiting

Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab

Non-small Cell Lung Cancer (NSCLC)Lung Cancer (Diagnosis)Small Cell Lung Cancer ( SCLC )
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest240 enrolled2 locationsNCT07510724
Recruiting
Phase 1Phase 2

68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer

SCLCSmall Cell Lung CancerSCLC,Extensive Stage+2 more
Peking University First Hospital30 enrolled1 locationNCT07508852
Recruiting
Phase 1Phase 2

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

Colorectal, CancerOvarian CancerCervical Cancer+7 more
Radiopharm Theranostics, Ltd61 enrolled4 locationsNCT07189871
Recruiting
Phase 1Phase 2

Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)

SCLC,Extensive StageSmall Cell Lung Cancer ( SCLC )Relapsed/Refractory SCLC
Beijing Biotech60 enrolled1 locationNCT07480213
Recruiting
Phase 1Phase 2

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Breast CancerTriple-Negative Breast CancerColorectal, Cancer+26 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting

A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC

Small Cell Lung Cancer ( SCLC )
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine500 enrolled1 locationNCT07434518
Recruiting
Phase 1Phase 2

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

Colorectal CarcinomaNon-small Cell Lung CancerBladder Cancer+4 more
Tasca Therapeutics150 enrolled13 locationsNCT07030257
Recruiting
Early Phase 1

177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors

Endometrial CancerNon-small Cell Lung CancerTNBC - Triple-Negative Breast Cancer+6 more
Radiopharm Theranostics, Ltd30 enrolled5 locationsNCT06305962
Recruiting
Phase 2

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

Small Cell Lung Cancer ( SCLC )
Alliance Foundation Trials, LLC.65 enrolled1 locationNCT07149363
Recruiting
Phase 1Phase 2

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

Solid TumorsER+ Breast CancerTriple Negative Breast Cancer(TNBC)+2 more
Jacobio Pharmaceuticals Co., Ltd.102 enrolled8 locationsNCT05490472